A Phase 2 interventional study of JP-1366 and JP-1366 placebo in GERD, sponsored by Onconic Therapeutics Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-13.
Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.
Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 12th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 2, and was the 41st registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19+
Incheon St.Mary's Hospital · Sites in Korea, Republic of
Ages 19+
Jeil Pharmaceutical Co., Ltd. · Sites in Korea, Republic of
Ages 19+
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19–75
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 19 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 6 · Phase 3 11 · Phase 4 8
First in 2006; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 188 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 54 across the 52 interventional studies, 2,000 across the 19 observational. Of the 51 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 71 have an industry lead sponsor. The 10 most frequent:
This study is registered under Onconic Therapeutics Inc., one of the names counted as Jeil Pharmaceutical Co., Ltd.. Under that name alone:
Onconic Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 9 are open to participants now.
Jeil Pharmaceutical Co., Ltd. has 6 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
1 of the studies in Gastroesophageal Reflux with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07678177HK inno.N CorporationAn Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical trial to evaluate the safety and efficacy of JP-1366 in patients with erosive gastroesophageal reflux disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JP-1366 A mg
Drug: JP-1366 · Drug: JP-1366 placebo · Drug: Esomeprazole placebo
JP-1366 B mg
Drug: JP-1366 · Drug: JP-1366 placebo · Drug: Esomeprazole placebo
JP-1366 C mg
Drug: JP-1366 · Drug: JP-1366 placebo · Drug: Esomeprazole placebo
Esomeprazole 40 mg
Drug: JP-1366 placebo · Drug: Esomeprazole 40mg
JP-1366, QD
JP-1366 placebo, QD
Esomeprazole 40mg, QD
Esomeprazole placebo, QD
Accumulated mucosal defect cure rate*(%) at Week 8 following study drug administration (%)
\* Erosion recovered to normal mucous membrane on upper gastrointestinal endoscopy
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2019 to primary completion in Oct 2020, 11 months.
Of 14 phase 2 interventional studies under Gastroesophageal Reflux, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zastaprazan